Oklahoma Board of Nursing 2501 N. Lincoln Blvd., Ste. 207 Oklahoma City, OK 73105 405-962-1800

CRNA Inclusionary Formulary

To be granted authority to select, order, obtain and administer drugs, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the *Rules of the Oklahoma Board of Nursing*, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [Oklahoma Nursing Practice Act], a CRNA is an Advanced Practice Registered Nurse who administers anesthesia in collaboration with a medical doctor, an osteopathic physician, a podiatric physician or a dentist licensed in this state and under conditions in which timely onsite consultation by such doctor, osteopath, podiatric physician or dentist is available. The Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary pursuant to 59 O.S. § 567.4b. [Oklahoma Nursing Practice Act].

Pursuant to 59 O.S. § 567.3a.10.h [Oklahoma Nursing Practice Act], "collaboration" means an agreement between a medical doctor, osteopathic physician, podiatric physician or dentist performing the procedure or directly involved with the procedure and the Certified Registered Nurse Anesthetist working jointly toward a common goal providing services for the same patient.

The following Board-approved *CRNA Inclusionary Formulary* lists drugs that may be ordered, selected, obtained or administered during the **perioperative** and **periobstetrical** periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs.

4:00 Antihistamine Drugs

4:04 <u>First Generation Antihistamines</u>
Diphenhydramine Hydrochloride
Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24)

12:00 Autonomic Drugs

12:04 Parasympathomimetic (Cholinergic) Agents

Neostigmine Bromide Physotigmine Salicylate Pyridostigmine Bromide

12:08 Anticholinergic Agents

12:08.08 Antimuscarinics/antispasmodics

Atropine Glycopyrrolate Ipratropium Bromide Scopolomine

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 1 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/22/1

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

12:12 Sympathomimetic (Adrenergic) Agents

12:12.04 α-Adrenergic Agonists

Midodrine

Phenylephrine

12:12.08 β-Adrenergic Agonists

12:12.08.04 Non-selective β-Adrenergic Agonists

Isoproterenol

12:12.08.08 Selective β₁-Adrenergic Agonists

Dobutamine

Dopamine

12:12.08.12 Selective β₂-Adrenergic Agonists

Albuterol/Levalbuterol

Formoterol

Indacterol

Metaproterenol

Salmeterol

Terbutaline Sulfate

12:12.12 α- and β-Adrenergic Agonists

Ephedrine

Epinephrine

Norepinephrine

Pseudoephedrine

12:16 Sympatholytic (Adrenergic Blocking) Agents

12:16.04 α-Adrenergic Blocking Agents

12:16.04.04 Non-selective α-Adrenergic Blocking Agents

Phentolamine

12:20 Skeletal Muscle Relaxants (all in this class approved including future new drugs)

12:20.04 Centrally Acting Skeletal Muscle Relaxants

Carisoprodol

Cyclobenzaprine

Metaxalone

Methocarbamol

Tizanidine

12:20.08 Direct-acting Skeletal Muscle Relaxants

Dantrolene Sodium

12:20.12 GABA-derivative Skeletal Muscle Relaxants

Baclofen

12:20.20 Neuromuscular Blocking Agents

Atracurium Besylate

Cisatracurium

Pancuronium Bromide

Rocuronium Bromide

Succinylcholine Chloride

Vecuronium Bromide

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 2 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

16:00 Blood Derivatives

Albumin Human Plasma Protein Fraction

Blood and Blood Components (not in AHFS)

20:00 Blood Formation, Coagulation, and Thrombosis

20:12 Antithrombotic Agents

20:12.04 Anticoagulants

20:12.04.12 Direct Thrombin Inhibitors

Bivalirudin

20:12.04.16 Heparins

Enoxaparin

Heparin

20:28 Antihemorrhagic Agents

20:28.08 Antiheparin Agents

Protamine Sulfate

20:28.16 Hemostatics

Aminocaproic Acid

Tranexamic Acid (TXA)

20:28.92 Antihemorrhagic Agents, Misc.

Idarucizumab

Andexanet Alfa

24:00 Cardiovascular Drugs

24:04 Cardiac Drugs

24:04.04 Antiarrhythmic Agents

24:04.04.04 Class Ia Antiarrhythmics

Disopyramide

Procainamide

Ouinidine

24:04.04.08 Class Ib Antiarrhythmics

Lidocaine

24:04.04.20 Class III Antiarrhythmics

Amiodarone

24:04.04.24 Class IV Antiarrhythmics

Adenosine

24:04.08 Cardiotonic Agents

Digoxin

24:08 Hypotensive Agents

24:08.16 Central α-Agonists

Clonidine

Methyldopa

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 3 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

24:08.20 Direct Vasodilators

Hydralazine

Sodium Nitroprusside

24:12 Vasodilating Agents

24:12.08 Nitrates and Nitrites

Nitrogylcerine

24:24 β-Adrenergic Blocking Agents

Atenolol

Esmolol Hydrochloride

Labetalol

Metoprolol

Nadolol

Propranolol

24:28 Calcium-Channel Blocking Agents

24:28.08 Dihydropyridines

Nicardipine

Nifedipine

24:28.92 Calcium-Channel Blocking Agents, Miscellaneous

Verapamil

24:32 Renin-Angiotensin-Aldosterone System Inhibitors

24:32.04 Angiotensin-Converting Enzyme Inhibitors

Captopril

Enalaprilat/Enalapril

28:00 Central Nervous System Agents

28:04 General Anesthetics (all in this class approved including future new drugs)

28:04.04 Barbiturates

Methohexital

28:04.16 Inhalation Anesthetics

28:04.92 General Anesthetics, Miscellaneous

Etomidate

Ketamine

Fospropofol

Propofol

28:08 Analgesics and Antipyretics

28:08.04 Nonsteroidal Antiflammatory Agents

28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors

Celecoxib

28:08.04.24 Salicylates

Aspirin

28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents

Ibuprofen

Indomethacin

Ketorolac

Meloxicam

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 4 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

28:08.08 Opiate Agonists (all in this class approved including future new drugs)

Codeine

Fentanyl

Hydrocodone

Hydromorphone

Levorphanol

Meperidine

Morphine

Remifentanil

Sufentanil Citrate

Tramadol

28:08.12 Opiate Partial Agonists (all in this class approved including future new

drugs)

Buprenorphine

Butorphanol

Nalbuphine

28:08.92 Analgesics and Antipyretic, Miscellaneous

Acetaminophen

Sodium Thiosalicylate

28:10 Opiate Antagonists (all in this class approved including future new drugs)

Nalmefene

Naloxone

Naltrexone

28:12 Anticonvulsants

28:12.04 Barbituates

Phenobarbital

28:12.08 Benzodiazepines

Clonazepam (see also 28:24.08)

28:12:12 Hydantoins

Ethotoin

Fosphenytoin

Phenytoin

28:12.92 Anticonvulsants, Miscellaneous

Carbamazepine

Felbamate

Gabapentin

Lamotrigine

Magnesium Sulfate

Valproate/Divalproex

28:16 Psychotherapeutic Agents

28:16.08 Antipsychotics

28:16.08.04 Atypical Antipsychotics

28:16.08.08 Butyrophenones

Haloperidol

Board Approved: 1/20/98

1 100 100 - 7 100 100 - 7 100 100

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 5 of 10

 $Board\ Revised:\ 9/30/99;\ 5/25/01;\ 5/28/02;\ 5/27/03;\ 5/25/04;\ 5/24/05;\ 5/29/07;\ 5/27/08;\ 5/19/09;\ 5/25/10;\ 7/26/11;$

 $5/22/12;\ 5/28/13;\ 7/14/14;\ 5/19/15;\ 5/24/16;\ 7/25/17;\ 5/22/18;\ 5/21/19;\ 11/10/20;\ 5/25/21;\ 7/26/22$

28:16.08.24 Phenothiazines

Perphenazine

Prochlorperazine

28:20 Anorexigenic Agents and Respiratory and CNS Stimulants

28:20.32 Respiratory and CNS Stimulants

Caffeine/Caffeine and Sodium Benzoate

Doxapram

28:24 Anxiolytics, Sedatives, and Hypnotics

28:24.04 Barbiturates (all in this class approved including future new drugs)

Phenobarbital

28:24.08 Benzodiazepines (all in this class approved including future new drugs)

Alprazolam

Chlordiazepoxide

Diazepam

Lorazepam

Midazolam

Remimazolam

Temazepam

28:24.92 Anxiolytics, Sedatives, and Hypnotics, Miscellaneous

Dexmedetomidine

Hydroxyzine

Promethazine

28:36 Antiparkinsonian Agents

28:36.08 Anticholinergic Agents

Benztropine Mesylate

28:92 Central Nervous System Agents, Miscellaneous

Flumazenil

36:00 Diagnostic Agents

36:40 Kidney Function

Indigo Carmine (Indigotindisulfonate)

36:56 Myasthenia Gravis

Edrophonium Chloride

40:00 Electrolytic, Caloric, and Water Balance

40:08 Alkalinizing Agents

Citrates (i.e., potassium citrate and citric acid, sodium citrate and citric acid, tricitrates)

Sodium Bicarbonate

Sodium Lactate

40:12 Replacement Preparations

Calcium Salts

Dextran 40

Electrolyte Solutions

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 6 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

 $5/22/12;\ 5/28/13;\ 7/14/14;\ 5/19/15;\ 5/24/16;\ 7/25/17;\ 5/22/18;\ 5/21/19;\ 11/10/20;\ 5/25/21;\ 7/26/22$

Hetastarch

Potassium Supplements

Sodium Chloride

40:20 Caloric Agents

Dextrose

Invert Sugar

40:24 Salt and Sugar Substitutes

40:28 Diuretics

40:28.08 Loop Diuretics

Bumetanide

Furosemide

40:28.12 Osmotic Diuretics

Mannitol

40:28.20 Thiazide Diuretics

Chlorothiazide

48:00 Respiratory Tract Agents (all in this class approved including future new drugs)

48:08 Antitussives

Benzonatate

Codeine

Dextromethorphan

Hydrocodone

48:16 Expectorants

Guaifenesin

Potassium Iodide (see also 68:36.08)

48:24 Mucolytic Agents

Acetylcysteine (see also 92:12)

52:00 Eye, Ear, Nose, and Throat (EENT) Preparations

52:16 Local Anesthetics

Benzocaine

Dyclonine

Proparacaine

Tetracaine

52:32 <u>Vasoconstrictors</u>

Epinephrine

Naphazoline

Oxymetazoline

Phenylephrine

Propylhexedrine

Tetrahydrolozine

52:40 Antiglaucoma Agents

52:40.12 Carbonic Anhydrase Inhibitors

Acetazolamide

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 7 of 10

 $Board\ Revised:\ 9/30/99;\ 5/25/01;\ 5/28/02;\ 5/27/03;\ 5/25/04;\ 5/24/05;\ 5/29/07;\ 5/27/08;\ 5/19/09;\ 5/25/10;\ 7/26/11;$

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

56:00 Gastrointestinal Drugs

56:04 Antacids and Adsorbents

Aluminum Carbonate

Aluminum Hydroxide

Aluminum Phosphate

Antacids

Calcium Carbonate

Charcoal, Activated

Dihydroxyaluminum Aminoacetate

Dihydroxyaluminum Sodium Carbonate

Magaldrate

Magnesium Carbonate

Magnesium Hydroxide

Magnesium Oxide

Magnesium Trisilicate

Sodium Bicarbonate

56:22 Antiemetics

56:22.08 Antihistamines

Dimenhydrinate

Meclizine

Prochlorperazine

Trimethobenzamide

56:22.20 5-HT₃ Receptor Antagonists

Dolasetron

Granisetron

Ondansetron

56:22.92 Antiemetics, Miscellaneous

Amisulpride

56:28 Antiulcer Agents and Acid Suppressants

56:28.12 Histamine H2-Antagonists

Cimetidine

Famotidine

Nizatidine

56:28.32 Protectants

Sucralfate

56:28.36 Proton-pump Inhibitors

Dexlansoprazole

Esomeprazole

Lansoprazole

Omeprazole

Pantoprazole

Rabeprazole

56:32 Prokinetic Agents

Metoclopramide

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 8 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

5/22/12, 5/26/13, 1/14/14, 5/12/13, 5/24/10, 1/25/17, 5/22/13, 5/24/13, 1/16/20, 5/25/21, 1/25/20, 5/26/20, 5/2

68:00 Hormones and Synthetic Substitutes

68:04 Adrenals (all in this class approved including future new drugs)

Beclomethasone

Betamethasone

Cortisone Acetate

Dexamethasone

Fludrocortisone

Flunisolide

Hydrocortisone

Methlyprednisolone

Prednisolone

Prednisone

Triamcinolone

68:20 Antidiabetic Agents

68:20.08 Insulins

68:20.08.04 Rapid-acting Insulins

Insulin Aspart

Insulin Glulisine

Insulin Lispro

68:20.08.08 Short-acting Insulins

Insulin Human

Insulin Isophane

68:20.08.16 Long-acting Insulins

Insulin Glargine

68:20.20 Sulfonylureas

Glimepiride

Glipizide

Glyburide

Tolazamide

Tolbutamide

68:22 Antihypoglycemic Agents

68:22.12 Glycogenolytic Agents

Glucagon

68:28 Pituitary

Corticotropin

Desmopressin

Vasopressin

68:44 Renin-Angiotensin-Aldosterone System (RAAS)

Angiotensin II

72:00 Local Anesthetics (all in this class approved including future new drugs)

Articaine

Bupivacaine

Chloroprocaine

Lidocaine

Mepivacaine

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 9 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11;

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

Prilocaine

Procaine

Ropivacaine

Tetracaine

76:00 Oxytocics

Carboprost Tromethamine

Dinoprostone

Ergonovine/Methergonovine

Oxytocin

84:00 Skin and Mucous Membrane Agents

84:04 Anti-infective

84:04.92 Local Anti-Infectives, Miscellaneous

Chlorhexidine gluconate

84:08 Antiprurities and Local Anesthetics (all in this class approved including future new

drugs)

Benzocaine

Dibucaine

Doxepin

Ethyl Chloride

Phenazopyridine

Pramoxine

86:00 Smooth Muscle Relaxants

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline

Theophyllines

92:00 Miscellaneous Therapeutic Agents

92:12 Antidotes

Acetylcysteine

Methylene Blue

Sugammadex

NOTE: ACLS Algorithm medications are approved and listed according to the AHFS classification system.

Regulatory Authority:

59 O.S. §567.4b.

Reference:

American Hospital Formulary Service®. *AHFS Drug Information* (2022). Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23

Page 10 of 10

 $Board\ Revised:\ 9/30/99;\ 5/25/01;\ 5/28/02;\ 5/27/03;\ 5/25/04;\ 5/24/05;\ 5/29/07;\ 5/27/08;\ 5/19/09;\ 5/25/10;\ 7/26/11;$

5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22